Shenzhen government-backed venture capital firm Shenzhen Capital Group Co., Ltd., has led a series B round worth of hundreds of millions of RMB in Shenzhen-based genetic sequencing company HaploX, according to Haplox’s announcement. Founded in 2014, HaploX focuses on the development and application of circulating tumor DNA (ctDNA) liquid biopsy technology. CtDNA is tumor-derived fragmented DNA in the bloodstream that is not associated with cells. Because ctDNA may reflect the entire tumor genome, liquid biopsies in the form of blood …

Shenzhen Capital Group Leads Series B Round In Genetic Sequencing Firm HaploX appeared first on China Money Network.